ACP, OpenEvidence partner on clinical AI

The collaboration aims to put trusted clinical evidence within reach during patient encounters.

By
Teraya Smith
November 9, 2026
2 min

MDSpire News

Objective:

The article describes ACP’s licensing agreement with OpenEvidence to make ACP clinical guidance and Annals of Internal Medicine content available through the AI-enabled clinical decision support platform.

Approach:

Agreement: ACP will license its clinical guidelines, guidance statements, practice points, and best practice advice to OpenEvidence.
Journal content: The agreement also covers published content from Annals of Internal Medicine.

Key Findings:

OpenEvidence is an AI-enabled clinical decision support platform.
ACP said the agreement will expand physicians’ access to clinical recommendations and published research at the point of care.
ACP represents approximately 163,000 members worldwide.
The announcement did not specify an implementation timeline or which portions of the journal’s content will be available.

Interpretation:

ACP President Jan K. Carney said access to ACP guidance and peer-reviewed Annals of Internal Medicine content through the platform can help physicians make more informed clinical decisions in real time and devote more time and attention to patient care.

Limitations:

The announcement provided no implementation timeline.
It did not identify which Annals of Internal Medicine content would be available through OpenEvidence.